Metabolomic studies have also evaluated serum TGF-β and IFN-γ levels in patients with chronic obstructive respiratory disease (COPD) and in those with both COPD and asthma, compared to smokers. This evidence concerns the gene TGFB1 and chronic obstructive pulmonary disease.